Zumsemetinib + Capecitabine + Zoledronic acid + Denosumab
Phase 1/2Recruiting 0 watching 0 views this weekπ€ Quiet
38
Development Stage
β
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
Conditions
Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
Trial Timeline
Jan 30, 2025 β May 31, 2032
NCT ID
NCT06374459About Zumsemetinib + Capecitabine + Zoledronic acid + Denosumab
Zumsemetinib + Capecitabine + Zoledronic acid + Denosumab is a phase 1/2 stage product being developed by United Therapeutics for Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06374459. Target conditions include Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer.
Hype Score Breakdown
Clinical
13
Activity
8
Company
7
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06374459 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer